source
- GSK receives FDA approval for ROS1 inhibitor Jideytro, marking its first lung cancer drugGSK's FDA approval of Jideytro, a ROS1 inhibitor for advanced non-small cell lung cancer patients with ROS1 gene fusions who have already received ROS1-directed therapy, was announced on Wednesday.…
- Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trialScancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCL…